OR WAIT 15 SECS
New CDMO facility supports early-stage API manufacturing and scale up.
Concept Life Sciences, a knowledge-based provider of integrated discovery, development, and analytical services, opened a new, clinical and niche commercial facility to support pharmaceutical and biotechnology companies throughout the development and manufacture of APIs. Located at Discovery Park in Sandwich, United Kingdom, the purpose-built facility offers a comprehensive range of services designed to allow partner organizations to take drug candidates through discovery, scale up, and into cGMP-compliant production. The company has several facilities throughout the UK.
“Pharmaceutical and biotech companies of all sizes are demanding high-quality, early-stage manufacturing capabilities that can readily scale up target molecules from grams to kilograms, and then into cGMP-compliant API manufacture all while mitigating the risk typically associated with moving between different stages of the drug development process,” said Dr Paul Doyle, chief scientific officer at Concept Life Sciences, in the June 18, 2019 press release. “Building on our depth of scientific expertise in medicinal and discovery chemistry, the new, specialist facility strengthens our support services so we can enable our partners to boost their productivity and deliver products to market faster and more efficiently.”
Source: Concept Life Sciences